| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Apr, 2026 | Apr, 2026 |
| Sales | 45,950 | 1,080 | 150 | 0 | 0 |
| Sales Growth | +4,154.63% | +620.00% | unch | unch | unch |
| Net Income | -48,880 | -71,800 | 4,180 | 0 | 0 |
| Net Income Growth | +31.92% | -1,817.70% | unch | unch | unch |
Septerna Inc (SEPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif.
Fiscal Year End Date: 12/31